E28 Stock Analysis: FRENCKEN | SG
Scientific & Technical Instruments | SG, Singapore | Market Cap: 971m SGD | 12M Return: 36% | SG1R43925234 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.5M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Frencken Group Limited is a Singapore-based investment holding company that provides original design manufacturing (ODM), original equipment manufacturing (OEM), and integrated contract manufacturing solutions across Singapore, the Netherlands, China, and Malaysia. The company operates through two segments: Mechatronics, which produces precision-engineered systems, electromechanical assemblies, and high-precision components for OEMs serving medical, semiconductor, analytical, pharmaceutical, industrial automation, and aerospace end-markets; and Integrated Manufacturing Services (IMS), which offers contract design and manufacturing for the automotive and office automation industries, including filters, plastic injection moulding, molds and dies, and automated assembly.
Founded in 1999 and classified under the GICS Electronic Components sub-industry, Frencken sits within the broader electronics manufacturing services (EMS) sector, serving diversified, high-specification end-markets such as semiconductor equipment, medical devices, and aerospace. Its business model spans the full product lifecycle, from design and prototyping to precision machining, assembly, testing, and turnkey project management.
- Semiconductor equipment capex cycle boosts Mechatronics revenue
- Medical device OEM outsourcing expands precision engineering order pipeline
- Office automation structural decline weighs on IMS segment margins
| Net Income: 39.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 6.64 > 1.0 |
| NWC/Revenue: 39.02% < 20% (prev 38.06%; Δ 0.96% < -1%) |
| CFO/TA 0.21 > 3% & CFO 166.7m > Net Income 39.1m |
| Net Debt (-58.9m) to EBITDA (86.2m): -0.68 < 3 |
| Current Ratio: 2.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (428.9m) vs 12m ago 0.43% < -2% |
| Gross Margin: 14.26% > 18% (prev 14.52%; Δ -0.26% > 0.5%) |
| Asset Turnover: 114.8% > 50% (prev 110.0%; Δ 4.89% > 0%) |
| Interest Coverage Ratio: 10.23 > 6 (EBIT TTM 54.7m / Interest Expense TTM 5.35m) |
| A: 0.43 (Total Current Assets 568.5m - Total Current Liabilities 230.9m) / Total Assets 784.2m |
| B: 0.48 (Retained Earnings 373.9m / Total Assets 784.2m) |
| C: 0.07 (EBIT TTM 54.7m / Avg Total Assets 753.3m) |
| D: 1.66 (Book Value of Equity 486.6m / Total Liabilities 293.8m) |
| Altman-Z'' = 6.61 = AAA |
| DSRI: 1.11 (Receivables 161.6m/134.0m, Revenue 865.1m/794.3m) |
| GMI: 1.02 (GM 14.52% / 14.26%) |
| AQI: 1.28 (AQ_t 0.05 / AQ_t-1 0.04) |
| SGI: 1.09 (Revenue 865.1m / 794.3m) |
| TATA: -0.16 (NI 39.1m - CFO 166.7m) / TA 784.2m) |
| Beneish M = -2.71 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at SGD 2.14 with a total of 3,859,600 shares traded. Over the past week, the price has changed by -3.17%, over one month by -17.69%, over three months by -13.01% and over the past year by +35.96%.
Current recommended Stop Loss: 1.90 (which is 11.2% or 2.7 ATR below the current price).
FRENCKEN has no consensus analysts rating.
P/E Trailing = 22.7778
P/E Forward = 14.8368
P/S = 1.1268
P/B = 1.4627
P/EG = 1.4397
Revenue TTM = 865.1m SGD
EBIT TTM = 54.7m SGD
EBITDA TTM = 86.2m SGD
Long Term Debt = 920k SGD (from longTermDebt, last quarter)
Short Term Debt = 53.2m SGD (from shortLongTermDebt, last quarter)
Debt = 64.1m SGD (Leases only: 64.1m)
Net Debt = -58.9m SGD (calculated: Debt 64.1m - CCE 123.0m)
Enterprise Value = 911.9m SGD (970.8m + Debt 64.1m - CCE 123.0m)
Interest Coverage Ratio = 10.23 (Ebit TTM 54.7m / Interest Expense TTM 5.35m)
EV/FCF = 6.20x (Enterprise Value 911.9m / FCF TTM 147.0m)
FCF Yield = 16.12% (FCF TTM 147.0m / Enterprise Value 911.9m)
FCF Margin = 17.00% (FCF TTM 147.0m / Revenue TTM 865.1m)
Net Margin = 4.52% (Net Income TTM 39.1m / Revenue TTM 865.1m)
Gross Margin = 14.26% ((Revenue TTM 865.1m - Cost of Revenue TTM 741.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 1.16 (Enterprise Value 911.9m / Total Assets 784.2m)
Interest Expense / Debt = 8.35% (Interest Expense 5.35m / Debt 64.1m)
Taxrate = 20.41% (10.1m / 49.4m)
NOPAT = 43.6m (EBIT 54.7m * (1 - 20.41%))
Current Ratio = 2.46 (Total Current Assets 568.5m / Total Current Liabilities 230.9m)
Debt / Equity = 0.13 (Debt 64.1m / totalStockholderEquity, last quarter 486.6m)
Debt / EBITDA = -0.68 (Net Debt -58.9m / EBITDA 86.2m)
Debt / FCF = -0.40 (Net Debt -58.9m / FCF TTM 147.0m)
Total Stockholder Equity = 459.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 5.19% (Net Income 39.1m / Total Assets 784.2m)
RoE = 8.51% (Net Income TTM 39.1m / Total Stockholder Equity 459.9m)
RoCE = 11.88% (EBIT 54.7m / Capital Employed (Equity 459.9m + L.T.Debt 920k))
RoIC = 8.54% (NOPAT 43.6m / Invested Capital 510.0m)
WACC = 10.26% (E(970.8m)/V(1.03b) * Re(10.50%) + D(64.1m)/V(1.03b) * Rd(8.35%) * (1-Tc(0.20)))
Discount Rate = 10.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 67.05 | Cagr: 0.06%
[DCF] Terminal Value 72.04% ; FCFF base≈123.2m ; Y1≈141.3m ; Y5≈207.9m
[DCF] Fair Price = 5.06 (EV 2.34b - Net Debt -58.9m = Equity 2.40b / Shares 473.6m; r=10.26% [WACC]; 5y FCF grow 15.0% → 2.50% )
Revenue Correlation: 99.76 | Revenue CAGR: 7.92% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=0.10 | Chg30d=-0.20% | Revisions=+17% | GrowthEPS=+10.7% | GrowthRev=+4.9%
EPS next Year (2027-12-31): EPS=0.12 | Chg30d=+0.59% | Revisions=+0% | GrowthEPS=+17.6% | GrowthRev=+9.3%
[Analyst] Revisions Ratio: +10% (up=4, down=3)